Last reviewed
Introduction
Regulatory requirements for peptide testing increase progressively through drug development. Understanding these requirements helps ensure efficient development programs and successful regulatory submissions.
Regulatory Framework
FDA Guidance
The FDA regulates peptide drugs primarily through:
- CDER: Center for Drug Evaluation and Research
- CBER: Center for Biologics Evaluation and Research (for larger peptides)
Key guidances:
- Guidance for Industry: ANDAs for Certain Highly Purified Synthetic Peptide Drug Products
- ICH guidelines adopted by FDA
ICH Guidelines
International Council for Harmonisation guidelines applicable to peptides:
Quality:
- Q1: Stability Testing
- Q2: Analytical Validation
- Q3A/B/C: Impurities
- Q6B: Specifications for Biotechnological Products
Safety:
- S2: Genotoxicity Testing
- S7: Safety Pharmacology
Efficacy:
- E6: Good Clinical Practice
- E8: General Considerations for Clinical Studies
Development Stage Requirements
Discovery/Research Phase
Minimal regulatory requirements, but good practices include:
- Basic identity confirmation (MS)
- Purity assessment (HPLC)
- Documentation of synthesis and testing
Preclinical Development
GLP Studies:
Testing of test article characterization:
- Identity (sequence confirmation)
- Purity and impurity profile
- Stability for study duration
- Homogeneity of formulations
Required documentation:
- Certificate of Analysis
- Analytical methods
- Stability data
IND-Enabling Studies
CMC Requirements:
- Manufacturing process description
- Control of critical process parameters
- Analytical methods (preliminary validation)
- Specifications and acceptance criteria
- Stability data (accelerated and initial real-time)
Impurity Qualification:
- Identify impurities >0.1%
- Qualify impurities in toxicology batches
- Establish justified limits
Clinical Development
Phase 1:
- Validated analytical methods
- Established specifications
- Ongoing stability studies
- GMP manufacturing
Phase 2/3:
- Process validation
- Full method validation
- Comprehensive stability data
- Comparability studies for process changes
NDA/BLA Submission
Complete CMC package:
- Full manufacturing description
- Validated methods with complete documentation
- Specification justification
- Stability data through proposed shelf life
- Container closure qualification
- Process validation
Analytical Method Requirements
Method Validation (ICH Q2)
Required validation parameters:
Identity Methods:
- Specificity
- Comparison to reference standard
Purity/Impurity Methods:
- Specificity
- Linearity
- Range
- Accuracy
- Precision (repeatability, intermediate)
- Detection limit
- Quantitation limit
- Robustness
Stability-Indicating Methods
Must demonstrate:
- Ability to detect degradation products
- Specificity for parent compound
- Forced degradation studies showing method capability
Specification Requirements
ICH Q6B Framework
Specifications should include:
Appearance:
- Physical description
- Color, clarity (solutions)
Identity:
- Specific for the peptide
- Usually MS or HPLC retention time + MS
Purity:
- HPLC purity
- Related substances limits
- Aggregate limits (if applicable)
Potency:
- Biological activity assay
- Required for therapeutic peptides
Safety:
- Endotoxin limits
- Bioburden/sterility
- Residual solvents
- Elemental impurities
